Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide

Shock

Volumn 36, Issue 5, 2011, Pages 510-516

  Yeh, Ching Hua ^a   Chou, Willy ^b,c   Chu, Chin Chen ^b,d   So, Edmund Cheung ^d   Chang, Huai Chia ^e   Wang, Jhi Joung ^d   Hsing, Chung Hsi ^b,d,e  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c Department of Rehabilitation ^*  (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

2 Methoxyestradiol; cytokines; nitric oxide; sepsis

Indexed keywords

2 METHOXYESTRADIOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CECUM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO SELECTION; IN VIVO STUDY; INTESTINE INJURY; INTRACELLULAR SIGNALING; KIDNEY INJURY; LETHALITY; LIGATION; LIVER INJURY; LUNG INJURY; MACROPHAGE; MOUSE; NONHUMAN; PERITONEAL FLUID LEVEL; PERITONEUM MACROPHAGE; PROTEIN BLOOD LEVEL; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; SEPSIS;

EID: 80054960493     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318231866f     Document Type: Article

References (35)

1. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ: Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 24:254-258, 2003. (Pubitemid 36555964)
2. Hsing CH, Lin MC, Choi PC, Huang WC, Kai JI, Tsai CC, Cheng YL, Hsieh CY, Wang CY, Chang YP, et al.: Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen speciesYregulated Akt/IKKbeta/NFkappaB signaling. PLoS One 6:e17598, 2011.
3. Bochud PY, Calandra T: Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326:262-266, 2003. (Pubitemid 36169594)
4. Sessler CN, Shepherd W: New concepts in sepsis. Curr Opin Crit Care 8:465-472, 2002.
5. Pribluda VS, ER Gubish Jr, Lavallee TM, Treston A, Swartz GM, Green SJ: 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19:173-179, 2000. (Pubitemid 32004707)
6. Lakhani NJ, Sarkar MA, Venitz J, Figg WD: 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165-172, 2003. (Pubitemid 36197457)
7. Schumacher G, Neuhaus P: The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 127:405-410, 2001. (Pubitemid 32524356)
8. Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, et al.: Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101:3606-3614, 2003. (Pubitemid 36857949)
9. Sattler M, Quinnan LR, Pride YB, Gramlich JL, Chu SC, Even GC, Kraeft SK, Chen LB, Salgia R: 2-Methoxyestradiol alters cell motility, migration, and adhesion. Blood 102:289-296, 2003. (Pubitemid 36759667)
10. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C: 2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10:8665-8673, 2004. (Pubitemid 40053435)
11. Mooberry SL: Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6:355-361, 2003. (Pubitemid 38173586)
12. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375, 2003. (Pubitemid 38340305)
13. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G: Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15:1460-1465, 2009.
14. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD: Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25:41-48, 2007. (Pubitemid 44657641)
15. Chen C, Hu Q, Yan J, Lei J, Qin L, Shi X, Luan L, Yang L, Wang K, Han J, et al.: Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model. J Neurochem 102:1831-1841, 2007. (Pubitemid 47329256)
16. Huerta-Yepez S, Baay-Guzman GJ, Garcia-Zepeda R, Hernandez-Pando R, Vega MI, Gonzalez-Bonilla C, Bonavida B: 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol 129:313-324, 2008.
17. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G: 2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogendeficient rats. Vascul Pharmacol 51:190-197, 2009.
18. Shand FH, Langenbach SY, Keenan CR, Ma SP, Wheaton BJ, Schuliga MJ, Ziogas J, Stewart AG: In vitro and in vivo evidence for anti-inflammatory properties of 2-methoxyestradiol. J Pharmacol Exp Ther 336:962-972, 2011.
19. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V: Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol 178:7516-7519, 2007. (Pubitemid 46898018)
20. Yeh CH, Cho W, So EC, Chu CC, Lin MC, Wang JJ, Hsing CH: Propofol inhibits lipopolysaccharide-induced lung epithelial cell injury by reducing hypoxia-inducible factor-1alpha expression. Br J Anaesth 106:590-599, 2011.
21. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
22. Hofer S, Steppan J, Wagner T, Funke B, Lichtenstern C, Martin E, Graf BM, Bierhaus A, Weigand MA: Central sympatholytics prolong survival in experimental sepsis. Crit Care 13:R11, 2009.
23. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG: 2-Methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res 11:1722-1732, 2005. (Pubitemid 40471833)
24. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(Suppl 1):52-57, 2005.
25. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983. (Pubitemid 13043132)
26. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453:807-811, 2008. (Pubitemid 351793778)
27. Zhou D, Matchett GA, Jadhav V, Dach N, Zhang JH: The effect of 2-methoxyestradiol, a HIF-1 alpha inhibitor, in global cerebral ischemia in rats. Neurol Res 30:268-271, 2008. (Pubitemid 351769420)
28. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, et al.: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79-84, 1990. (Pubitemid 20021861)
29. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL, et al.: Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21: 318-327, 1993. (Pubitemid 23097025)
30. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843, 1994. (Pubitemid 24169697)
31. Spight D, Trapnell B, Zhao B, Berclaz P, Shanley TP: Granulocyte- macrophagecolony-stimulating factorYdependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice. Shock 30: 434-442, 2008.
32. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ: 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24:209-216, 2003. (Pubitemid 36267088)
33. Aktan F: iNOS-mediated nitric oxide production and its regulation. Life Sci 75:639-653, 2004. (Pubitemid 38686696)
34. Berg D, Sonsalla R, Kuss E: Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 103:282-288, 1983. (Pubitemid 13093835)
35. Kroncke KD, Fehsel K, Kolb-Bachofen V: Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 113:147-156, 1998. (Pubitemid 28352831)